Lixte more than doubles on promising cancer drug data; tops premarket gainers

NOMAD Power Solutions

12/04/2022 14:20

** Drug developer's shares  LIXT.O  surge 157% to $2.83
premarket- top pct gainer across U.S. exchanges, set to open at
over 3-mth high if gains hold
    ** LIXT announces new preclinical data on its lead cancer
drug candidate, LB-100, at the American Association for Cancer
Research (AACR) meeting  urn:newsml:reuters.com:*:nGNX1Gv1Kk
    ** Initial studies reveal LB-100 induces further activation
of the signaling pathways (which control cancer progression) in
a number of cancers with mutations in the KRAS gene, rendering
them particularly vulnerable to anti-cancer therapy - LIXT
    ** The studies were done by the Netherlands Cancer Institute
in collaboration with LIXT 
    ** Up to last close, LIXT had fallen 7.6% YTD, vs a 14.3%
decline in the Nasdaq composite index  .IXIC 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))